Company Overview
Immunome is a clinical-stage targeted oncology company committed to developing first-in-class and best-in-class targeted cancer therapies. We are advancing an innovative portfolio of therapeutics, drawing on leadership that previously played key roles in the design, development, and commercialization of cutting-edge therapies, including antibody-drug conjugate therapies. Our pipeline includes varegacestat, a late-clinical stage GSI; IM-1021, a clinical-stage ROR1 ADC; and IM-3050, a FAP-targeted radiotherapy that recently received IND clearance. We are also advancing a broad portfolio of early stage ADCs pursuing undisclosed solid tumor targets.
Position Overview
Immunome is seeking a highly organized, proactive, and detail-oriented Contracts Manager to join its legal team. This role is ideal for a legal professional who excels at managing contract lifecycles while also being able to provide broader support across corporate, transactional, and compliance functions. The ideal candidate will have experience in the biotech or pharmaceutical industries and be comfortable supporting cross-functional teams in a fast-paced, dynamic environment.
Responsibilities
Contracts Management
- Serve as the primary administrator for the company’s contract lifecycle management (CLM) system (e.g., Ironclad), including contract intake, routing, tracking, and archiving.
- Draft, review, and coordinate the execution of standard agreements, including NDAs, consulting agreements, SOWs, CTAs, MTAs, and vendor agreements.
- Identify and assess legal and business risks and escalate as necessary.
- Ensure all contractual activities comply with internal policies, applicable laws and regulations, and industry best practices.
- Maintain accurate records of contract status, key terms, and renewal/termination dates.
- Collaborate with internal stakeholders (R&D, Finance, Clinical) to ensure timely and compliant contract processing, including renewal or cancellation of existing contracts.
- Assist with improving and maintaining contract templates, playbooks, and process workflows.
Qualifications
- Bachelor’s degree required. Paralegal certificate or JD, strongly preferred.
- A minimum of 5 years of contracts management experience, biotechnology or life sciences industry experience is required.
Knowledge and Skills
- Deep understanding of contract structures, terms, and risk assessment.
- Proficiency with contract lifecycle management tools (e.g., Ironclad, ContractWorks).
- Exceptional organizational and time management skills.
- Ability to manage multiple priorities and deadlines.
- Strong interpersonal, communication, and client service skills; capable of working collaboratively across departments.
- Commitment to integrity and ethical conduct and ability to protect confidential information.
- Familiarity with software tools like DocuSign, Microsoft Office Suite, and Adobe Acrobat.
- Experience supporting clinical trial or research-related contracts, preferred.
E/E/O
Immunome, Inc. is an equal opportunity employer. We celebrate diversity and are committed to creating an inclusive environment for all employees.
E-Verify
Immunome, Inc. is a participant in E-Verify. Please review the following notices: E-Verify Participation Poster | Right to Work Poster (English) | Right to Work Poster (Spanish).
What We Do
Immunome is a clinical-stage targeted oncology company committed to developing first-in-class and best-in-class targeted therapies designed to improve outcomes for cancer patients. We are advancing an innovative portfolio of therapeutics, drawing on leadership that previously played key roles in the design, development, and commercialization of cutting-edge targeted cancer therapies, including antibody-drug conjugate therapies (ADCs). Our most advanced pipeline programs are varegacestat (formerly AL102), a gamma secretase inhibitor which is currently in a Phase 3 trial for treatment of desmoid tumors; IM-1021, a ROR1-targeted ADC which is currently in a Phase 1 trial; and IM-3050, a FAP-targeted radioligand, which recently received IND clearance. Our pipeline also includes IM-1617, IM-1335, and IM-1340, all of which are preclinical ADCs pursuing undisclosed targets with expression in multiple solid tumors.
